What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To evaluate the efficacy of a new 10 mg fitusiran dose in maintaining antithrombin levels in hemophilia patients.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Population modeling shows fitusiran 10 mg increases target antithrombin levels in hemophilia, suggesting broader treatment options.

To evaluate the efficacy of a new 10 mg fitusiran dose in maintaining antithrombin levels in hemophilia patients.
Assessment of fitusiran dosing regimen in a Phase 3 open-label extension study
Utilization of a population semi-mechanistic model for dose validation
Simulation of participant responses to dosing options based on clinical data
10 mg dose predicted to reduce discontinuations due to low antithrombin levels
6.7% predicted discontinuation rate at 20 mg Q2M dose
0.96% and 2.8% predicted discontinuation rates for 10 mg Q2M and 15 mg QM doses respectively

Abhimanyu Yarramaneni (2025) studied this question.

View Full Paper

Ask AI

Bookmark